# US 8,278,319 B2 · Substituted spiroamine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,319 B2
- Document ID: US8278319B2
- Status: Granted
- Kind: B2
- Application number: 12/608,543
- Filed: 2009-10-29
- Published: 2010-05-06
- Granted: 2012-10-02
- Earliest claimed: 2008-10-29
- Assignees: Gruenenthal GmbH
- Inventors: Melanie Reich; Stefan Oberboersch; Stefan Schunk; Ruth Jostock; Sabine Hees; Michael Engels
- Web page: https://patentgrep.com/patent/US8278319B2

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 221/20: Spiro-condensed ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Substituted spiroamine compounds corresponding to the formula (I) In which m, n, o, p, Q, r, s, t, R1, R2, R3, R4a, R4b, R5a, R5b, R6a, R6b, R7, R8, R9, R10 and R11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin 1 receptor.

## Claims

### Claim 1

A substituted spiroamine compound corresponding to formula (I):
wherein
r, s and t each independently represent 0, 1 or 2;
m, n, o and p each represent 2;
Q denotes a single bond, —O— or —CH2—;
R1 denotes CH(aryl)2, aryl, heteroaryl or an aryl or heteroaryl group bonded via a C1-3 alkylene group;
R2 and R3 are as defined under (i) or (ii):
(i) R2 denotes H, C1-6 alkyl, C3-8 cycloalkyl, bicyclic 8-12-membered carbocyclyl, CH(aryl)2, aryl or heteroaryl, or
R2 denotes a C3-8 cycloalkyl, bicyclic 8-12-membered carbocyclyl, CH(aryl)2, aryl or heteroaryl group bonded via a C1-6 alkylene group or C2-6 alkenylene group; and
R3 denotes H, F, Cl, Br, I, —CF3, —OCF3, OH, COOR16, CONR17R18, O—C1-6 alkyl,
C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl wherein
R16 denotes C1-6 alkyl;
R17 and R18 are as defined under (v) or (vi):
(v) R17 and R18 each independently denote H or C1-6 alkyl; or
(vi) R17 and R18 together with the nitrogen atom linking them form a heterocycle which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl and heteroaryl and/or anellated with a saturated, mono- or polyunsaturated or aromatic ring system which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl and heteroaryl,
wherein said heterocycle may be saturated, mono- or polyunsaturated but not aromatic, is 4-,5-,6- or 7-membered, in addition to the N-heteroatom to which R8 and R9 are bound optionally may also contain one or more further heteroatoms or a heteroatom group selected from the group consisting of N, NR19, O, S, S═O and S(═O)2, the ring system is 4-,5-,6- or 7-membered, can contain at least one heteroatom or a heteroatom group selected from the group consisting of N, NR20, O, S, S═O and S(═O)2, wherein
R19 denotes H, or a C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl group or an aryl, heteroaryl or C3-8 cycloalkyl group bonded via a C1-3 alkylene group, and
R20 denotes H, or a C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl group, or an aryl, heteroaryl or C3-8 cycloalkyl group bonded via a C1-3 alkylene group; or
R3 denotes a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-6 alkylene group or C2-6 alkenylene group; or
(ii) R2 and R3 together with the —N—(CR4aR4b)r—CH— group linking them form a heterocycle which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl and heteroaryl and/or anellated with at least one optionally substituted aryl or heteroaryl,
wherein said heterocycle may be saturated or mono- or polyunsaturated, but is not aromatic, is 4-, 5-, 6- or 7-membered, and in addition to the N-heteroatom to which R2 is bound optionally may also contain one or more heteroatoms or heteroatom groups independently selected from the group consisting of N, NR12, O, S, S═O or S(═O)2; wherein
R12 denotes H, C1-6 alkyl, —C(═O)—R13, C3-8 cycloalkyl, aryl, heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group, and
R13 denotes C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group;
R4a, R4b, R5a, R5b, R6a and R6b each independently represent H, F, Cl, Br, I, —CF3, —OCF3, OH, SH, O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl; or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-6 alkylene group or C2-6 alkenylene group;
R7 denotes aryl, heteroaryl or for an aryl or heteroaryl group bonded via a C1-3 alkylene group;
R8 and R9 are as defined under (iii) or (iv):
(iii) R8 and R9 each independently denote H, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl or heteroaryl or a C3-8 cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group; or
(iv) R8 and R9 together with the nitrogen atom linking them form a heterocycle which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl, C1-3 alkylene-C3-8 cycloalkyl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl and/or anellated with a saturated, mono- or polyunsaturated or aromatic ring system which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl, C1-3 alkylene-C3-8-cycloalkyl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl,
wherein said heterocycle may be saturated, mono- or polyunsaturated but not aromatic, is 4-, 5-, 6- or 7-membered, in addition to the N-heteroatom to which R8 and R9 are bound optionally may also contain at least one further heteroatom or a heteroatom group selected from the group consisting of N, NR14, O, S, S═O and S(═O)2, the ring system is 4-, 5-, 6- or 7-membered, can contain at least one heteroatom or a heteroatom group selected from the group consisting of N, NR15, O, S, S═O and S(═O)2; wherein
R14 denotes a group selected from the group consisting of H, C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl or for an aryl, heteroaryl or C3-8 cycloalkyl bonded via a C1-3 alkylene group, and
R15 denotes a group selected from the group consisting of H, C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl or for an aryl, heteroaryl or C3-8 cycloalkyl bonded via a C1-3 alkylene group; and
R10 and R11 each independently represent 0 to 4 substituents each independently selected from the group consisting of F, OH, C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl and C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-6 alkylene group;
wherein said C1-6 alkyl, C2-6 alkenyl, C1-3 alkylene, C1-6 alkylene, C2-6 alkenylene, carbocyclyl, 3- to 8-membered heterocycloalkyl, C3-8 cycloalkyl, aryl and heteroaryl groups may each be unsubstituted or mono- or polysubstituted with identical or different substituents, and said C1-6 alkyl, C2-6 alkenyl, C1-3 alkylene, C1-6 alkylene and C2-8 alkenylene groups may each be branched or unbranched;
or a physiologically compatible salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, wherein said compound is in the form of an isolated stereoisomer.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein said compound is in the form of a mixture of stereoisomers in any mixing ratio.

### Claim 4 (depends on 3)

A compound as claimed in claim 3, wherein said mixture is a racemic mixture.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein R1 denotes a phenyl, naphthyl, indolyl, benzofuranyl, benzothiophenyl, benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, quinolinyl, isoquinolinyl or CH(phenyl)2 group, or a phenyl or naphthyl group bonded via a C1-3 alkylene group; wherein said groups may each be unsubstituted or mono- or polysubstituted, equally or differently, with substituents independently selected from the group consisting of —O—C1-3 alkyl, C1-6 alkyl, C3-6 cycloalkyl, F, Cl, Br, CF3, OCF3, OH, phenyl, phenoxy, naphthyl, thiazolyl, thienyl and pyridinyl.

### Claim 6 (depends on 5)

A compound as claimed in claim 5, wherein R1 denotes a phenyl, naphthyl, benzothiophenyl, benzooxadiazolyl, quinolinyl, isoquinolinyl or thienyl group or a phenyl group bonded via a C1-3 alkylene group; wherein said groups may be unsubstituted or mono- or polysubstituted.

### Claim 7 (depends on 1)

A compound as claimed in claim 1, wherein in formula (I) the substructure (Ac I)
denotes one of the following groups:
wherein
R200 denotes 0 to 4 substituents each independently selected from the group consisting of F, Cl, —CF3, ═O, —O—CF3, —OH, —O—C1-6 alkyl and C1-6 alkyl or two adjacent R200 groups together form an anellated aryl or heteroaryl ring;
R210 denotes 0 to 4 substituents each independently selected from the group consisting of —O—C1-3 alkyl, C1-6 alkyl, F, Cl, Br, I, CF3, OCF3, OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl;
R12 denotes H, C1-6 alkyl, —C(═O)—R13, C3-8 cycloalkyl, aryl or heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group, and
R13 denotes C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group.

### Claim 8 (depends on 1)

A compound as claimed in claim 1, wherein
R2 denotes H, C1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl or a C3-6 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group, in each case unsubstituted or mono- or polysubstituted with identical or different substituents; and
R3 denotes H, F, Cl, —CF3, —OH, —O—C1-6 alkyl, C1-6 alkyl, aryl or heteroaryl; or an aryl or heteroaryl group bonded via a C1-3 alkylene group, in each case unsubstituted or mono- or polysubstituted with identical or different substituents.

### Claim 9 (depends on 8)

A compound as claimed in claim 8, wherein
R2 denotes H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, phenyl, pyridinyl or a phenyl or pyridinyl group bonded via a C1-3 alkylene group; and
R3 denotes H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl or pyridinyl.

### Claim 10 (depends on 1)

A compound as claimed in claim 1, wherein in formula (I) the following substructure:
denotes a —CH2—, —(CH2)2—, —(CH2)3—, —(CH2)4— or —CH2—O—CH2 group.

### Claim 11 (depends on 1)

A compound as claimed in claim 1, wherein R4a, R4b, R5a, R5b, R6a and R6b are each independently selected from the group consisting of H, F, Cl, CF3, OH, OCF3 and OCH3.

### Claim 12 (depends on 1)

A compound as claimed in claim 1, wherein R7 denotes a phenyl, naphthyl, thienyl, thiazolyl, pyridinyl or benzyl group which may be unsubstituted or mono- or polysubstituted with substituents independently selected from the group consisting of C1-4 alkyl, O—C1-4 alkyl, F, Cl, CF3, OCF3 and —CN.

### Claim 13 (depends on 1)

A compound as claimed in claim 1, wherein R8 and R9 each independently denote H or unsubstituted or mono- or polysubstituted C1-6 alkyl.

### Claim 14 (depends on 1)

A compound as claimed in claim 1, wherein R8 and R9 together with the nitrogen atom linking them form a heterocycle corresponding to formula (II)
wherein
Z denotes O, S, NR15a, CH2 or C(halogen)2, wherein
R15a denotes H; C1-6 alkyl; aryl, heteroaryl, or an aryl or heteroaryl group bonded via a C1-3 alkylene group;
x and y each independently represent 0, 1 or 2, with the proviso that x+y=0, 1, 2 or 3, and
R300 denotes 0 to 4 substituents each independently selected from the group consisting of C1-6 alkyl, —O—C1-6 alkyl, OH, CF3, F, aryl, heteroaryl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl;
wherein said C1-6 alkyl, C1-3 alkylene, aryl and heteroaryl groups may be unsubstituted or mono- or polysubstituted with identical or different substituents.

### Claim 15 (depends on 1)

A compound as claimed in claim 1, wherein R10 and R11 each independently represent 0 to 4 substituents each independently selected from the group consisting of C1-6 alkyl, —O—C1-6 alkyl, OH, CF3, F, aryl, heteroaryl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl.

### Claim 16 (depends on 1)

A compound as claimed in claim 1, wherein the substructure
denotes one of the following groups:
wherein
R10 and R11 each independently represent 0 to 4 substituents independently selected from the group consisting of C1-6 alkyl, —O—C1-6 alkyl, OH, CF3, F, aryl, heteroaryl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl;
R300 denotes 0 to 4 substituents independently selected from the group consisting of C1-6 alkyl, —O—C1-6 alkyl, OH, CF3, F, aryl, heteroaryl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl; and
R310 denotes 0 to 4 substituents independently selected from the group consisting of F, Cl, Br, C1-6 alkyl, O—C1-6 alkyl, CF3, OCF3 and CN.

### Claim 17 (depends on 1)

A compound as claimed in claim 1, corresponding to formula (Ia)
wherein
s and t each independently represent 0, 1 or 2;
Q denotes a single bond, —O— or —CH2—;
R1 denotes phenyl or naphthyl, each unsubstituted or mono- or polysubstituted, identically or differently with substituents each independently selected from the group consisting of —O—C1-3 alkyl, C1-6 alkyl, F, Cl, Br, CF3, OCF3 and OH;
R2 and R3 are as defined under (i) or (ii):
(i) R2 denotes H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, aryl, heteroaryl, or
R2 denotes an aryl or heteroaryl group bonded via a C1-3 alkylene group, and
R3 denotes H or phenyl, wherein the phenyl may be unsubstituted or mono- or polysubstituted with substituents selected from the group consisting of F, Cl, —CF3, —OCF3, OH, methyl and methoxy; or
(ii) R2 and R3 together with the —N—CH— group linking them form a heterocycle which optionally may be substituted at one or more of its carbon ring members with one or more substituents each independently selected from the group consisting of F, Cl, Br, I, —NH2, —CF3, ═O, —O—CF3, —OH, —SH, —O—C1-6 alkyl, C1-6 alkyl, C3-8 cycloalkyl, aryl and heteroaryl and/or anellated with at least one optionally substituted aryl or heteroaryl group,
wherein said heterocycle may be saturated or mono- or polyunsaturated, but is not aromatic, is 4-, 5-, 6- or 7-membered, and in addition to the N-heteroatom to which R2 is bound optionally may also contain one or more heteroatoms or heteroatom groups independently selected from the group consisting of N, NR12, O, S, S═O or S(═O)2; wherein
R12 denotes H, C1-6 alkyl, —C(═O)—R13, C3-8 cycloalkyl, aryl, heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group, and
R13 denotes C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl or a C3-8 cycloalkyl, aryl or heteroaryl group bonded via a C1-3 alkylene group;
R7 denotes a phenyl, naphthyl, thienyl, thiazolyl, pyridinyl or benzyl group, wherein said group may be unsubstituted or mono- or polysubstituted with substituents each independently selected from the group consisting of C1-4 alkyl, O—C1-4 alkyl, F, Cl, CF3, OCF3 and —CN;
R8 and R9 are as defined under (iii) or (iv):
(iii) R8 and R9 are each independently selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl; or
(iv) R8 and R9 together with the nitrogen atom linking them form a heterocycle corresponding to formula (II)
wherein
Z denotes O, S, NR15a, CH2 or CF2, wherein
R15a denotes H; methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, naphthyl or pyridinyl or
R15a represents a phenyl, naphthyl or pyridinyl group bonded via a C1-3 alkylene group;
x and y each independently represent 0, 1 or 2, with the proviso that x+y=0, 1, 2 or 3, and
R300 denotes 0 to 4 substituents each independently selected from the group consisting of C1-6 alkyl, —O—C1-6 alkyl, OH, CF3, F, aryl, heteroaryl, C1-3 alkylene-aryl and C1-3 alkylene-heteroaryl.

### Claim 18 (depends on 1)

A compound as claimed in claim 1, selected from the group consisting of:
1
2-((1-(4-Methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)methoxy)-1-(9-phenyl-9-(pyrrolidin-1-yl)- 3-azaspiro[5.5]undecan-3-yl)ethanone
2
1-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-(((S)-1- (4-methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)methoxy)ethanone
3
N-Cyclopropyl-N-(2-(2-(9-(dimethylamino)- 9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2- oxoethoxy)ethyl)-4-methoxy-2,6- dimethylbenzolsulfonamide
4
1-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4- methoxy-2,6-dimethylphenylsulfonyl)- indolin-2-yl)methoxy)ethanone
5
N-((1R)-3-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-3-oxo-1- phenylpropyl)naphthalene-2-sulfonamide
6
2-(((S)-1-(2-Chloro-6- methylphenylsulfonyl)piperidin-2- yl)methoxy)-1-(9-(dimethylamino)-9-phenyl- 3-azaspiro[5.5]undecan-3-yl)ethanone
7
3-(1-(4-Chloro-2,5- dimethylphenylsulfonyl)piperidin-2-yl)-1- (9-(dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)propan-1-one
8
1-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-4-(1-(4- methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)butan-1-one
9
1-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-(1-(3- (trifluoromethyl)phenylsulfonyl)piperidin- 2-yl)ethan-1-one
10
(3R)-3-(2-(9-(Dimethylamino)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-oxoethyl)-4- (4-methoxy-2,6-dimethylphenylsulfonyl)- 3,4-dihydropyrazin-2(1H)-one
11
1-(9-(Dimethylamino)-9-(3-fluorophenyl)-3- azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4- methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)methoxy)ethanone
12
1-(9-(Azetidin-1-yl)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4- methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)methoxy)ethanone
13
1-(9-(3,3-Difluoroazetidin-1-yl)-9-phenyl-3- azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4- methoxy-2,6- dimethylphenylsulfonyl)piperidin-2- yl)methoxy)ethanone
CC-01
1-[3-(3-Fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-2-[1-[[3- (trifluoromethyl)phenyl]sulfonyl]-piperidin- 2-yl]-ethanone
CC-02
1-[3-(3-Fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-4-[1-[(4- methoxy-2,6-dimethyl-phenyl)sulfonyl]- piperidin-2-yl]-butan-1-one
CC-03
1-[3-(3-Fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-2-[[1-[(4- methoxy-2,6-dimethyl-phenyl)sulfonyl]- piperidin-2-yl]-methoxy]-ethanone
CC-04
N-Cyclopropyl-N-[2-[2-[3-(3-fluorophenyl)-3- pyrrolidin-1-yl-9-azaspiro[5.5]undecan-9-yl]- 2-oxo-ethoxy]-ethyl]-4-methoxy-2,6- dimethyl-benzenesulfonic acid amide
CC-05
2-[[1-[(2-Chloro-6-methyl-phenyl)sulfonyl]- piperidin-2-yl]-methoxy]-1-[3-(3- fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]ethanone
CC-06
2-Chloro-N-cyclopropyl-N-[2-[2-[3-(3- fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-2-oxo-ethoxy]- ethyl]-6-methyl-benzenesulfonic acid amide
CC-07
3-[1-[(4-Chloro-2,5-dimethyl- phenyl)sulfonyl]-piperidin-2-yl]-1-[3-(3- fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-propan-1-one
CC-08
N-[3-[3-(3-Fluorophenyl)-3-pyrrolidin-1-yl-9- azaspiro[5.5]undecan-9-yl]-3-oxo-1-phenyl- propyl]-naphthalene-2-sulfonic acid amide
CC-09
2-Chloro-N-cyclopropyl-N-[2-[2-(3- dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-2-oxo-ethoxy]- ethyl]-6-methyl-benzenesulfonic acid amide
CC-10
1-(3-Dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-2-[1-[[3- (trifluoromethyl)phenyl]sulfonyl]-piperidin- 2-yl]-ethanone
CC-11
1-(3-Dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-2-[[1-[(4- methoxy-2,6-dimethyl-phenyl)sulfonyl]- piperidin-2-yl]-methoxy]-ethanone
CC-12
N-Cyclopropyl-N-[2-[2-(3-dimethylamino-3- thiophen-2-yl-9-azaspiro[5.5]undecan-9-yl)- 2-oxo-ethoxy]-ethyl]-4-methoxy-2,6- dimethyl-benzenesulfonic acid amide
CC-13
2-[[1-[(2-Chloro-6-methyl-phenyl)sulfonyl]- piperidin-2-yl]-methoxy]-1-(3- dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-ethanone
CC-14
3-[1-[(4-Chloro-2,5-dimethyl- phenyl)sulfonyl]-piperidin-2-yl]-1-(3- dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-propan-1-one
CC-15
N-[3-(3-Dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-3-oxo-1-phenyl- propyl]-naphthalene-2-sulfonic acid amide
CC-16
1-(3-Dimethylamino-3-thiophen-2-yl-9- azaspiro[5.5]undecan-9-yl)-4-[1-[(4- methoxy-2,6-dimethyl-phenyl)sulfonyl]- piperidin-2-yl]-butan-1-one

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1 and at least one pharmaceutically acceptable carrier or auxiliary substance.
